Your browser is no longer supported. Please, upgrade your browser.
Settings
CDTX Cidara Therapeutics, Inc. daily Stock Chart
CDTX [NASD]
Cidara Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.21 Insider Own1.00% Shs Outstand24.02M Perf Week-4.40%
Market Cap104.49M Forward P/E- EPS next Y-2.37 Insider Trans- Shs Float24.02M Perf Month0.00%
Income-59.10M PEG- EPS next Q-0.61 Inst Own74.60% Short Float4.66% Perf Quarter-7.45%
Sales- P/S- EPS this Y4.20% Inst Trans34.71% Short Ratio8.62 Perf Half Y-37.41%
Book/sh3.48 P/B1.25 EPS next Y14.70% ROA-85.30% Target Price13.19 Perf Year-32.82%
Cash/sh4.30 P/C1.01 EPS next 5Y- ROE-113.50% 52W Range3.65 - 8.80 Perf YTD-36.03%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.57% Beta1.99
Dividend %- Quick Ratio7.10 Sales past 5Y- Gross Margin- 52W Low19.18% ATR0.31
Employees61 Current Ratio7.10 Sales Q/Q- Oper. Margin- RSI (14)48.55 Volatility5.50% 7.31%
OptionableYes Debt/Eq0.12 EPS Q/Q-14.20% Profit Margin- Rel Volume0.43 Prev Close4.25
ShortableYes LT Debt/Eq0.12 EarningsAug 08 Payout- Avg Volume129.75K Price4.35
Recom1.40 SMA203.45% SMA50-9.15% SMA200-26.74% Volume55,642 Change2.35%
Jul-26-18Initiated Citigroup Buy $8
Apr-21-17Initiated Raymond James Strong Buy
Apr-17-17Reiterated H.C. Wainwright Buy $18 → $14
Apr-12-17Initiated Ladenburg Thalmann Buy $11.25
Apr-11-17Resumed Wedbush Outperform $13
Feb-22-17Upgrade WBB Securities Sell → Hold $7.25
Feb-22-17Reiterated H.C. Wainwright Buy $25 → $18
Dec-21-16Resumed Leerink Partners Outperform
Dec-19-16Initiated H.C. Wainwright Buy $25
Sep-23-16Downgrade WBB Securities Hold → Sell $10.50
Oct-09-15Upgrade WBB Securities Sell → Hold $13
May-11-15Initiated Wedbush Outperform $22
May-11-15Initiated Needham Buy $20
May-11-15Initiated Leerink Partners Outperform $24
May-11-15Initiated Jefferies Buy $25
Apr-23-15Initiated WBB Securities Sell $13
Aug-08-18 04:54PM  Cidara Therapeutics: 2Q Earnings Snapshot Associated Press +6.76%
04:30PM  Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-30-18 08:00AM  Cidara Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks -7.87%
Jun-15-18 08:00AM  Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences Business Wire +7.48%
Jun-06-18 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 PR Newswire
May-23-18 08:00AM  Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidaras Rezafungin for the Treatment of Invasive Fungal Infections Business Wire +6.12%
May-21-18 08:15AM  Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections Business Wire
07:30AM  Cidara Therapeutics Announces Offering of Common Stock and Warrants GlobeNewswire
May-11-18 05:12AM  Cidara Therapeutics: 1Q Earnings Snapshot Associated Press
May-10-18 04:05PM  Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-20-18 10:17AM  Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-04-18 08:00AM  Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting Business Wire
Mar-21-18 08:00AM  Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin GlobeNewswire
07:40AM  Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin ACCESSWIRE
Mar-19-18 08:50AM  Options Traders Expect Huge Moves in Cidara Therapeutics (CDTX) Stock Zacks -24.05%
07:42AM  Cidara Therapeutics' stock soars toward 13-month high after positive drug trial results MarketWatch
07:30AM  Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin GlobeNewswire
Mar-08-18 08:00AM  Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting GlobeNewswire +10.88%
Mar-01-18 04:05PM  Cidara Announces Appointment of Chrysa Mineo as Independent Director GlobeNewswire +5.97%
Feb-28-18 05:03AM  Cidara Therapeutics reports 4Q loss Associated Press
Feb-27-18 04:32PM  Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Jan-30-18 10:18AM  The Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice Chair PR Newswire
Jan-29-18 08:00AM  Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting GlobeNewswire
Jan-09-18 12:55PM  2018 Could Be Hallmark Year For These Two Antifungal Companies GuruFocus.com
Jan-04-18 08:00AM  Newly Published Journal of Antimicrobial Chemotherapy Supplement Provides Insights into the Future of Echinocandin Therapy for Invasive Fungal Infections GlobeNewswire
Nov-28-17 08:30AM  Cidara Therapeutics Completes Enrollment in Phase 2 STRIVE Trial Evaluating Novel Antifungal Rezafungin (CD101 IV) in Invasive Fungal Infections GlobeNewswire
Nov-13-17 08:30AM  Cidara Therapeutics Named a San Diego Metro Area 2017 Top Workplace GlobeNewswire
Nov-08-17 09:12PM  Edited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMT Thomson Reuters StreetEvents
05:05PM  Cidara Therapeutics reports 3Q loss Associated Press
04:01PM  Cidara Provides Corporate Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
11:00AM  Cidara Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-01-17 04:05PM  Cidara Therapeutics to Report Third Quarter 2017 Financial Results and Provide Corporate Update GlobeNewswire
Oct-19-17 09:00AM  Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock GlobeNewswire +8.66%
Sep-25-17 08:00AM  Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting GlobeNewswire
Sep-18-17 04:05PM  Cidara Therapeutics to Present at Two Upcoming Conferences GlobeNewswire
Sep-07-17 08:30AM  Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress GlobeNewswire
Sep-06-17 07:05AM  T2 Biosystems and Cidara Therapeutics Announce Partnership for Commercial Placement of T2Dx Instruments to Support CD101 Drug Trials GlobeNewswire -5.00%
Aug-09-17 11:48PM  Cidara Therapeutics reports 2Q loss Associated Press -6.47%
Aug-01-17 08:30AM  Cidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC) Business Wire
Jul-06-17 08:30AM  Cidara Therapeutics to Participate in Anti-Infectives Panel Discussion at the 2017 Infectious Diseases Summit Business Wire -8.11%
Jun-19-17 10:17AM  Antimicrobial Working Group Members to Participate in 2017 BIO International Convention Panel PR Newswire
Jun-15-17 08:00AM  Cidara Therapeutics to Participate in the 2017 BIO International Convention Business Wire
May-30-17 08:30AM  Cidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association Business Wire -5.93%
May-10-17 05:46PM  Cidara Therapeutics reports 1Q loss Associated Press
05:07PM  Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results GlobeNewswire
08:40AM  Is a Surprise Coming for Cidara Therapeutics (CDTX) This Earnings Season? Zacks
Apr-25-17 08:30AM  Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer Business Wire
Apr-17-17 08:30AM  Cidara Therapeutics to Present Data on Novel Antifungal CD101 and Cloudbreak Antibacterial Immunotherapy at ECCMID and SID Annual Meetings Business Wire
Apr-07-17 09:30AM  The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics Zacks
Apr-06-17 09:32AM  3 of the Best & Worst Performing Drug Stocks of Q1 Zacks
Mar-31-17 05:10PM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Mar-30-17 12:00PM  Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First CloudbreakTM Antibiotic Immunotherapy Business Wire
Mar-29-17 07:30AM  Cidara Therapeutics to Host Investor Day on April 6, 2017 GlobeNewswire
Mar-23-17 04:30PM  Arbutus Announces Appointment of Daniel Burgess to Board of Directors GlobeNewswire +5.67%
Mar-21-17 01:04PM  CIDARA THERAPEUTICS, INC. Financials
Mar-15-17 07:25PM  Cidara Therapeutics reports 4Q loss Associated Press +5.76%
05:23PM  Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-22-17 04:12PM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
10:40AM  Is The Cidara Therapeutics Inc (CDTX) Crash An Opportunity? Insider Monkey
09:25AM  Cidara Yeast Infection Gelm Fails Phase 2 Trial Investopedia
06:58AM  Cidara Therapeutics upgraded by WBB Securities
Feb-21-17 07:33AM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi -38.46%
07:30AM  Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC GlobeNewswire
Jan-11-17 04:54PM  Antimicrobials Working Group Announces New Leadership Team PR Newswire
Jan-09-17 09:03AM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-04-17 07:30AM  Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis Business Wire +5.91%
Dec-14-16 08:30AM  Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics Lead Antifungal CD101 Business Wire
Dec-13-16 08:23AM  Hedge Funds Arent Crazy About Cidara Therapeutics Inc (CDTX) Anymore at Insider Monkey
Nov-29-16 12:03PM  Cidara Therapeutics, Inc. :CDTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
Nov-28-16 08:30AM  Cidara Therapeutics Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies Business Wire
Nov-25-16 12:00PM  Is Cidara Therapeutics (CDTX) Stock a Solid Choice Right Now?
Nov-10-16 06:12PM  Cidara Therapeutics reports 3Q loss +7.39%
04:11PM  Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results GlobeNewswire
04:08PM  CIDARA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
08:30AM  Cidara Therapeutics to Present Data on Novel Antifungal CD101 at the Global Joint Conference of ICHS and INFOCUS Business Wire
Nov-08-16 04:05PM  Cidara Therapeutics to Present at the Stifel 2016 Healthcare Conference GlobeNewswire
Nov-02-16 07:30AM  Cidara Therapeutics and Square 1 Bank Announce $20 Million Credit Facility GlobeNewswire
Oct-24-16 08:00AM  Cidara Therapeutics Announces Data from Studies of Novel Antifungal CD101 to be Presented at ACCP and IDWeek Annual Meetings Business Wire
Oct-13-16 09:20AM  Cidara Therapeutics Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Oct-07-16 04:10PM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta -10.54%
09:00AM  Cidara Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Oct-06-16 04:06PM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:02PM  Cidara Therapeutics Announces Commencement of Public Offering of Common Stock GlobeNewswire
Oct-03-16 04:04PM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off
Sep-28-16 09:02AM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-21-16 08:30AM  Cidara Therapeutics Selects First Development Candidate from its CloudbreakTM Immunotherapy Discovery Platform Business Wire
Sep-20-16 04:05PM  Cidara Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology GlobeNewswire
Sep-19-16 05:02PM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-01-16 04:05PM  Cidara Therapeutics Announces Clinical Management Team Changes Business Wire
04:01PM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors or
Aug-11-16 05:20PM  Cidara Therapeutics reports 2Q loss
04:12PM  Cidara Reports Second Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
04:03PM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
Aug-09-16 07:30AM  Cidara Therapeutics Announces Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting Business Wire
Jul-06-16 07:00AM  Cidara Therapeutics to Present at the Cantor Fitzgerald Annual Healthcare Conference GlobeNewswire
Jul-05-16 07:00AM  Cidara Therapeutics Expands Management Team GlobeNewswire
06:04AM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jun-24-16 04:06PM  CIDARA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-09-16 07:30AM  Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis Business Wire
Jun-08-16 07:30AM  Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016 Business Wire
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stein JeffreyPresident & CEOMay 23Buy4.70212,7661,000,000268,320May 24 05:16 PM
BIOTECH TARGET N V10% OwnerNov 15Buy7.5760,000453,9662,295,272Nov 16 12:19 PM
Stein JeffreyPresident & CEOSep 12Buy6.797,35049,90751,851Sep 12 05:49 PM